Reaction
Colorectal Cancer Metastatic reporting signals
As of the last recalculation, Colorectal Cancer Metastatic appears in 2,258 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is PANITUMUMAB (PRR 684.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Panitumumab | 768 | 684.4 | 719.8 |
| Regorafenib | 320 | 295.9 | 304.3 |
| Fluorouracil Cream, 0.5% | 561 | 89.9 | 90.5 |
| Fluorouracil | 561 | 88.6 | 89.3 |
| Oxaliplatin | 525 | 84.7 | 85.3 |
| Leucovorin Calcium | 130 | 66.5 | 66.9 |
| Trifluridine And Tipiracil | 74 | 65.7 | 66.2 |
| Irinotecan Hydrochloride | 77 | 57.1 | 57.5 |
| Bevacizumab | 567 | 56.0 | 56.3 |
| Cetuximab | 123 | 38.2 | 38.4 |
| Encorafenib | 27 | 25.4 | 25.5 |
| Capecitabine | 163 | 17.6 | 17.6 |
| Aflibercept | 50 | 15.1 | 15.1 |
| Granisetron Hydrochloride | 8 | 7.1 | 7.1 |
| Granisetron | 8 | 7.1 | 7.1 |
| Loperamide Hydrochloride Oral | 6 | 5.4 | 5.4 |
| Prochlorperazine Maleate | 5 | 5.0 | 5.0 |
| Lapatinib | 7 | 4.2 | 4.2 |
| Trametinib | 9 | 3.4 | 3.4 |